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New therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate 
receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence 
mGluR1 expression in different clinically relevant breast cancer subgroups and determined its 
association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues 
were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The 
prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and 
correlated with metastasis‑free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast 
cancer tissues had mGluR1 expression. In estrogen receptor (ER)‑negative tumors, 31% (n = 18/58) 
had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, 
p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple‑
negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was 
significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 
16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. 
In ER‑negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic 
marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, 
especially for the more aggressive TNBC.
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MFS  Metastasis-free survival
mGluR1  Metabotropic glutamate receptor 1 (protein)
OS  Overall survival
PR  Progesterone receptor
TMA  Tissue microarray
TNBC  Triple-negative breast cancer
Breast cancer is the most frequent and lethal cancer in women worldwide with approximately 2.1 million newly 
diagnosed breast cancer cases each  year1. In the Western society, approximately one in eight women will develop 
invasive breast cancer during their  life2. Although many women are effectively treated with specific therapies 
directed at the estrogen receptor (ER) and human epidermal growth factor type 2 receptor (HER2), 15% of breast 
cancers do not overexpress hormone receptors (ER and progesterone receptor (PR)) nor HER2 and are known 
as triple-negative breast cancer (TNBC). Women with TNBC cannot be treated with hormonal therapies nor 
therapies targeting HER2 and have a relatively poor  outcome3.
ER and HER2 are not solely treatment targets in breast cancer. These receptors are also known prognostic 
markers as are age and tumor-related factors including tumor size, lymph node status and tumor  grade4–7. A 
previous study identified tumor expression of metabotropic glutamate receptor 1 (mGluR1/GRM1) as another 
possible prognostic  marker8. This study was the first to show that ER-positive breast cancer is significantly more 
likely to express mGluR1 than ER-negative tumors. In another dataset of primary ER-positive and adjuvant 
tamoxifen-treated patients, low GRM1 expression associated with a longer distant metastasis-free survival (MFS) 
as compared to higher GRM1  expression8. The prognostic value of mGluR1/GRM1 expression in other breast 
cancer subgroups is unknown.
Metabotropic glutamate receptors are a family of G-protein coupled receptors, that bind the excitatory neu-
rotransmitter glutamate; mGluR1 belongs to the mGluR Group I  family9,10. Although mGluR1 is best known for 
its role in nervous system development, function and pathology, by mediating neuronal excitability and synaptic 
plasticity, its significance in tumorigenesis has been  demonstrated11–14. Overexpression of mGluR1 in a mouse 
model unexpectedly produced melanomas with 100%  penetrance11. Subsequently, it was demonstrated that 
mGluR1 was expressed in more than 60% of human melanoma  tissues15. Currently it is known that mGluR1 is 
expressed in substantial proportions of breast cancer, renal cell cancer and prostate cancer with indications that 
mGluR1 functions as an oncogene in these  tumors8,12,13,16,17. In addition to being a prognostic marker, mGluR1 
may also serve as a novel therapeutic target for the treatment of many cancers including breast  cancer13,18. Despite 
the promise of mGluR1 as prognostic  marker8 and potential treatment target in breast  cancer13,18, all published 
studies are based on relatively small cohorts and have not been validated.
In the current study, we evaluated mGluR1 expression in a not previously described cohort consisting of 
consecutive primary breast cancer patients. Additionally, we aimed to determine the prognostic value of mGluR1 
expression in hormone receptor and/or HER2 positive and negative breast cancer subgroups in this independent 
and representative cohort.
Methods
Patients, tumor tissue samples and databases. In this retrospective study, all tissues were derived 
from consecutive patients with primary breast cancer who were operated in the Erasmus University Medical 
Center from 2000 through 2005. In total 465 eligible tumors were analyzed. 71 cases were excluded due to miss-
ing values and other factors depicted in Fig. 1, resulting in a final number of 394 tissues for data analysis. Of 
all these patients complete clinical follow-up information was available until 2017. This study was performed 
in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(http://www.feder a.org/codes -condu ct) and used coded tumor tissues remaining after the routine procedure to 
diagnose the disease. According to this Code of Conduct, no informed consent is needed for this study. This pro-
cedure, including the need for informed consent, was waived and approved by the Medical Ethics Committee of 
the Erasmus MC (approval number MEC 02.953). Reporting Recommendations for Tumor Marker Prognostic 
Studies were followed (REMARK)19.
To confirm the prognostic value of mGluR1 at the RNA level, we consulted (partially) publicly available data 
from four independent breast cancer cohorts: (1) Affymetrix U133-A array data of 866 breast cancer patients, 
including 142 with  TNBC20, (2) TCGA data from which 166 TNBC cases were  extracted21,22, (3) RNAseq data of 
41 TNBC from Erasmus MC cohort (Hammerl D. et al. unpublished data), (4) RNAseq data of 36 TNBC patients 
from BASIS cohort containing 266 primary breast cancer  cases23.
Tissue microarray and immunohistochemical evaluation. Formalin-fixed paraffin-embedded 
(FFPE) tissue blocks were selected to be captured in tissue microarray (TMA) by using hematoxylin/eosin-
stained tissue sections. A breast pathologist graded the eligible tumors, determined the histological subtype, and 
marked three representative areas of the tumors. From each of the three selected areas, a core was extracted with 
a 0.6 mm needle and put in a blank receiver block (280 cores per block) using the Automated Tissue Arrayer 
ATA-27 (Beecher Instruments Inc, Sun Prairie, WI). Tumor grade was defined according to the modified Bloom-
Richardson  score7, and histology type was assessed on whole tissue sections prior to preparing the  TMA24.
Sections from each TMA block were cut (4 µm) and stained for ER, PR, mGluR1 and HER2 expression in 
triplicate. Primary antibodies and used conditions are listed in Additional file 1. ER, PR and mGluR1 antibodies 
were stained with the EnVision method (Dako, Glostrup, Denmark) and the HER2 staining with the HercepT-
est (Dako). Within the TMA, positive and negative control tissues were included containing tumor cell lines 
with known levels of HER2, ER and PR expression. mGluR1 transfected and untransfected Chinese hamster 
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ovary (CHO) cells were used as controls for mGluR1  staining25. After staining, slides were converted to digital 
images using the Virtual Slide Scanner NanoZoomer 2.0-HT (Hamamatsu, Hamamatsu-City, Japan). These 
digital images were uploaded in our TMA database (Distiller, Slidepath, Dublin, Ireland). For mGluR1 the 
staining quantity (percentage of positive stained tumor cells) and intensity (0 = negative, 1 = weak, 2 = moder-
ate, 3 = strong) was independently scored and consolidated by well trained technicians (Fig. 2). Only staining of 
invasive tumor cells was scored and scoring was done manually for all images. The percentage of the positively 
stained breast tumor cells was calculated relative to the total tumor cell count of 3 separate cores per tumor. 
mGluR1 was considered positive if > 25% of tumor cells had a membrane (diffuse and/or apical) staining pattern. 
Positive ER and PR cells were recorded only if staining was seen within the nuclei and the cut-off used to classify 
tumors as ER-positive or PR-positive was > 10% positive tumor cell nuclei. HER2 was considered positive for 
moderate to strong (3 +) intact membranous staining of > 30% of the tumor cells. HER2 staining tumors with a 
weak to moderate (2 +) staining aspect (and > 10% of the tumor cells) were additionally subjected to fluorescence 
in situ hybridization with the HER2FISH pharmDx Kit (Dako) and scored according to the kit guidelines. These 
tumors were considered HER2 positive when the HER2 gene was amplified.
Statistical analysis. Statistical analysis was performed using IBM SPSS Statistics 25. The relationship of 
patient and tumor characteristics with mGluR1 expression in the different subgroups was investigated using 
the Pearson Chi-Square test or the Fisher-Exact test when appropriate. In the entire cohort and in relevant sub-
groups univariate and multivariate Cox regression analysis was performed to identify which factors were associ-
ated with survival and for the different variables their hazard ratio (HR) with 95% confidence interval (95% CI) 
were calculated. For survival, metastasis-free survival (MFS) and overall survival (OS) were used as end points 
with MFS defined as the time from diagnosis to the first distant metastasis and OS as the time from diagnosis 
until patient’s death. All traditional risk factors were included in the model and mGluR1 expression was added 
to this base model. The Kaplan–Meier method was used for generating survival curves to visualize MFS and OS. 
Log-rank tests were used to test for differences between survival curves. Kaplan–Meier estimates and Log-rank 
tests were also used for relationship analysis between intensity of mGluR1 staining or a percentage of positively 
stained tumor cells (high vs low in both instances) and survival (MFS and OS). All p values were two sided and 
were considered statistically significant when below 0.05.
Ethics approval and consent to participate. This study was performed in accordance with the Code 
of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.feder a.org/codes 
-condu ct) and used coded tumor tissues remaining after the routine procedure to diagnose the disease. Accord-
ing to this Code of Conduct, no informed consent is needed for this study. This procedure, including the need 
for informed consent, was waived and approved by the Medical Ethics Committee of the Erasmus MC (approval 
number MEC 02.953).
Figure 1.  Flowchart of primary breast cancer tissues included in this study.
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Results
Patient and tumor characteristics. In total 394 patients were included in this breast cancer cohort and 
demographics and tumor characteristics are shown in Table 1. Most patients (n = 297; 75%) were between 41 and 
70 years of age. At diagnosis the majority had no lymph node metastasis (n = 233; 59%) and a T1 tumor (n = 267, 
68%). In the entire cohort 85% was ER-positive, 74% PR-positive, 12% had a HER2 amplification and 11% had 
neither a HER2 amplification nor hormone receptor expression (TNBC). Adjuvant chemotherapy was adminis-
tered in 158 patients (40%) while 179 (45%) received adjuvant hormone therapy.
mGluR1 is frequently expressed in breast cancer tissue. mGluR1 membrane staining was positive 
in more than half (n = 219; 56%) of the breast cancer tissues (Table 1). There was a diffuse membrane staining 
in 37% of the mGluR1 positive tumors and the remaining 63% had an apical staining pattern. In most mGluR1 
positive tumors (85%) the quantity of mGluR1 stained tumor cells was ≥ 50% while in 62% of these tumors the 
quantity of the mGluR1 expressing tumor cells was ≥ 80%. Examples of mGluR1 protein staining are shown 
in Fig.  2. Testing for association of mGluR1 expression with clinicopathological characteristics showed that 
mGluR1 expression was associated with a lower tumor grade and with ER-positive and PR-positive tumors 
(Table 1). There was no relationship with age, nodal involvement and tumor size. The percentage of tumor cells 
expressing mGluR1 differed between breast cancer subgroups. ER-positive and PR-positive tumors expressed 
mGluR1 (~ 60%) almost twice as frequent as ER or PR negative tumors (31% and 40% respectively). Among 
TNBC a quarter expressed mGluR1 contrary to 59% in non-TNBC tumors. No difference was observed in 
mGluR1 expression in relation to HER2 status.
Invasive ductal carcinoma was the most prevalent histological subtype (77%) and expressed mGluR1 in 
54% while the less frequent tubular (4.6%) and papillary (2.0%) breast cancer subtypes were almost exclusively 
mGluR1 positive. All tumors of the medullary subtype (1.3%) were negative for mGluR1 (Additional file 2).
No association of mGluR1 expression with prognosis in the entire cohort. All 394 patients were 
included for survival analysis. The median follow-up time was 94 months (range 5–181 months). All known 
prognostic factors and mGluR1 expression were included in the analysis of MFS (Table 2). Univariate analysis 
showed that expression of mGluR1 protein was not associated with MFS (HR 1.65, 95% CI 0.89–3.04, p = 0.111) 
in the entire cohort. To evaluate which of the clinical parameters are independently associated with MFS, we 
used multivariate Cox regression analysis and this showed that a larger tumor size, more involvement of lymph 
nodes and no-treatment with chemotherapy were prognostic factors for worse outcome. Also, mGluR1 expres-
sion was not associated with OS in univariate analysis (HR 1.33, 95% CI 0.98–3.13, p = 0.285) (Additional file 3). 
Additional file 4 shows the relation between mGluR1 expression and MFS and OS, depicted in Kaplan–Meier 
Figure 2.  Scoring of immunohistochemical mGluR1 staining on TMA. Representative examples of mGluR1 
staining in breast cancer tissues are shown. In these examples staining quantity (% of tumor cells) is scored as 
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curves. We did not find a relation between a higher intensity of mGluR1 staining or a higher percentage of 
stained tumor cells and prognosis in the entire cohort (p = 0.057 and p = 0.82 respectively).
Unfavorable outcome with mGluR1 expression in different breast cancer subgroups. We sub-
sequently examined the prognostic value of mGluR1 expression in different breast cancer subgroups. mGluR1 
expression was associated with a significantly shorter MFS in ER-negative breast cancer and in TNBC (Table 3).
Eighteen of the 58 ER-negative tumors (31%) were mGluR1-positive. In ER-negative tumors, mGluR1 expres-
sion was associated with higher age and more lymph node involvement (Additional file 5). Most patients (n = 43) 
in this ER-negative subgroup were treated with adjuvant chemotherapy. In univariate Cox regression analysis, 
mGluR1 expression and involvement of more lymph nodes were significantly associated with a shorter MFS 
(Table 4a). In the multivariate model, when corrected for known prognostic factors, only mGluR1 expression 
remained as an independent predictor for a poor MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046). Figure 3a shows 
Kaplan–Meier estimates of MFS. Poor OS was significantly associated with involvement of more lymph nodes 
and mGluR1 expression in univariate analysis (HR 7.46, 95% CI 1.91–29.16, p = 0.004). However, none of the 
Table 1.  Baseline characteristics and the association with mGluR1 expression in the entire cohort. *As 





n (%) n (%) n (%)
All patients 394 (100.0) 219 (55.6) 175 (44.4)
Age 0.248#
≤ 40 42 (10.7) 23 (54.8) 19 (45.2)
> 40− ≤ 55 174 (44.2) 91 (52.3) 83 (47.7)
> 55− ≤ 70 123 (31.2) 71 (57.7) 52 (42.3)
> 70 55 (14.0) 34 (61.8) 21 (38.2)
T-stage 0.902#
T1 267 (67.8) 147 (55.1) 120 (44.9)
T2 111 (28.2) 64 (57.7) 47 (42.3)
T3 11 (2.8) 5 (45.5) 6 (54.5)
T4 5 (1.3) 3 (60.0) 2 (40.0)
N-stage 0.156#
N0 233 (59.1) 126 (54.1) 107 (45.9)
N1 113 (28.7) 60 (53.1) 53 (46.9)
N2 48 (12.2) 33 (68.8) 15 (31.3)
Tumor grade < 0.001#
1 114 (28.9) 91 (79.8) 23 (20.2)
2 192 (48.7) 92 (47.9) 100 (52.1)
3 88 (22.3) 36 (40.9) 52 (59.1)
ER status* < 0.001
pos 336 (85.3) 201 (59.8) 135 (40.2)
neg 58 (14.7) 18 (31.0) 40 (69.0)
PR status* < 0.001
pos 291 (73.9) 178 (61.2) 113 (38.8)
neg 103 (26.1) 41 (39.8) 62 (60.2)
HER2 status* 0.969
pos 47 (11.9) 26 (55.3) 21 (44.7)
neg 347 (88.1) 193 (55.6) 154 (44.4)
TN status < 0.001
yes 44 (11.2) 11 (25.0) 33 (75.0)
no 350 (88.8) 208 (59.4) 142 (40.6)
Chemotherapy 0.014
Yes 158 (40.1) 76 (48.1) 82 (51.9)
No 236 (59.9) 143 (60.6) 93 (39.4)
Hormonal therapy 0.126
Yes 179 (45.4) 107 (59.8) 72 (40.2)
No 215 (54.6) 112 (52.1) 103 (47.9)
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predictors were significant in a multivariate model (mGluR1 HR 5.24, 95% CI 0.90–30.60, p = 0.066) (Additional 
file 6a; for Kaplan–Meier estimates of OS see Additional file 7a).
Forty-four patients had TNBC with mGluR1 expression in 11 patients (25%) (Additional file 8). Age and 
adjuvant chemotherapy associated significantly with mGluR1 expression. In univariate analysis mGluR1 expres-
sion and involvement of more lymph nodes were associated with a shorter MFS, while in the multivariate model 
only mGluR1 expression remained significant (HR 8.60, 95% CI 1.06–20.39, p = 0.044) (Table 4b). Kaplan–Meier 
estimates of MFS are shown in Fig. 3b. Only mGluR1 expression was significantly associated with OS in both 
univariate (HR 8.61, 95% CI 1.55–47.81, p = 0.014) and multivariate analysis (HR 16.07, 95% CI 1.16–223.10, 
p = 0.039) (Additional file 6b; for Kaplan–Meier estimates of OS see Additional file 7b).
In PR-negative breast cancer, mGluR1 expression was associated with unfavorable MFS in both univariate 
and multivariate analysis (additional file 9). As shown in Table 3, there was no prognostic value of mGluR1 
expression in ER-positive breast cancer. Additional file 10 shows Kaplan–Meier estimates of MFS and OS as a 
function of mGluR1 expression in ER-positive breast cancer.
Table 2.  Univariate and multivariate analysis of MFS in the entire cohort. *As retrieved from TMA. mGluR1 
was not added in the multivariate base model with known prognostic markers because no significance was 
achieved in univariate regression analysis.
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age
> 55 versus ≤ 55 0.77 0.42–1.41 0.396 0.41 0.16–1.05 0.062
T-stage
T2-4 versus T1 5.11 2.78–9.42  < 0.001 3.31 1.68–6.51 0.001
N-stage
N1 versus N0 4.19 1.97–8.90  < 0.001 4.04 1.60–10.17 0.003
N2 versus N0 8.83 4.00–19.47  < 0.001 7.47 2.86–19.54  < 0.001
Tumor grade
2 versus 1 1.81 0.76–4.31 0.180 1.23 0.49–3.08 0.665
3 versus 1 4.68 1.99–11-02  < 0.001 2.03 0.75–5.48 0.164
ER status*
Pos versus neg 0.41 0.22–0.79 0.007 0.26 0.04–1.59 0.146
PR status*
Pos versus neg 0.55 0.30–0.99 0.047 0.53 0.18–1.56 0.249
HER2 status*
Pos versus neg 2.07 1.00–4.28 0.051 1.37 0.48–3.91 0.558
TN status
Yes versus no 1.92 0.93–3.97 0.080 0.60 0.13–2.99 0.530
mGluR1
Pos versus neg 1.65 0.89–3.04 0.111
Chemotherapy
Yes versus no 1.75 0.98–3.13 0.058 0.22 0.08–0.59 0.003
Hormonal therapy
Yes versus no 1.88 1.04–3.38 0.036 1.86 0.58–5.97 0.297
Table 3.  Prognostic value of mGluR1 expression in clinically relevant breast cancer subgroups. Univariate 
cox-regression analysis of MFS in different breast cancer subgroups (as retrieved from TMA).
Subgroups n
mGluR1 Positive versus 
Negative
HR 95% CI p value
ER positive 336 1.23 0.60–2.52 0.577
ER negative 58 7.09 2.17–23.15 0.001
HER2 positive 47 7.26 0.91–58.12 0.062
HER2 negative 347 1.31 0.68–2.53 0.427
TN no 350 1.51 0.75–3.05 0.251
TN yes 44 5.23 1.40–19.60 0.014
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GRM1 RNA expression in TNBC is not associated with outcome. We also performed survival anal-
ysis for GRM1 RNA expression in TNBC patients from several cohorts. First, we studied Affymetrix U133-A 
array data in a cohort of 866 breast cancer patients, including 142 with  TNBC20. In the entire cohort, the three 
GRM1 probes were low responsive with barely any variation in gene expression, questioning the validity of the 
probes. Therefore, we did not use this cohort. Then we studied RNAseq data in TNBC patients from three dif-
ferent breast cancer cohorts. No significant relationship between GRM1 RNA expression level and outcome in 
TNBC was  observed21–23 (additional file 11).
Discussion
In the current study we demonstrate that mGluR1 expression is an independent, unfavorable prognostic factor in 
ER-negative breast cancer and in TNBC. To the best of our knowledge, this is the first study that shows an associa-
tion between outcome and mGluR1 protein expression in hormone receptor negative breast cancer and TNBC.
This primary breast cancer cohort is a representative cohort, containing 15% ER-negative tumors and 11% 
 TNBC24. Overall, we found that mGluR1 is frequently expressed in breast cancer with mGluR1 positivity in 56% 
of the tumors and this is in line with previous studies in which a similar percentage positivity was  reported8,26. 
Also, a consistent distribution is seen regarding the histological subtypes, in which half of the invasive ductal 
carcinomas express mGluR1 and one third of the invasive lobular  carcinomas26. Expression of mGluR1 in rela-
tion to hormone receptor status, with ER/PR-positive tumors having double the amount of mGluR1 expression 
than hormone receptor negative tumors, was also concordant to a previous  study8. This last observation suggests 
that expression of mGluR1 may be influenced by hormonal stimulation. Alternatively, the difference in mGluR1 
expression may merely reflect cell type specific differences between hormone negative and positive tumors.
Table 4.  Univariate and multivariate analysis of MFS in ER-negative breast cancer and TNBC. *As retrieved 
from TMA. Univariate and multivariate analysis of MFS in: a ER-negative breast cancer. TN status was 
excluded in multivariate cox-regression analysis due to correlation with HER2 status; b TNBC.
(A)
ER-negative breast cancer
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age
 > 55 versus ≤ 55 1.51 0.51–4.49 0.459 0.76 0.13–4.57 0.765
T-stage
T2-3 versus T1 1.83 0.61–5.45 0.279 1.63 0.37–7.12 0.517
N-stage
N1-N2 versus N0 5.26 1.62–17.13 0.006 4.03 0.93–17.47 0.063
Tumor grade
3 versus 1–2 1.46 0.40–5.31 0.568 1.68 0.42–6.69 0.462
HER2 status*
Pos versus neg 1.69 0.52–5.48 0.385 1.49 0.42–5.31 0.543
TN status
Yes versus no 0.67 0.21–2.17 0.504
mGluR1
Pos versus neg 7.09 2.17–23.15 0.001 5.00 1.03–24.35 0.046
Chemotherapy
Yes versus no 0.357 0.10–1.06 0.065 0.43 0.08–2.26 0.317
(B)
TNBC
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age
 > 55 versus ≤ 55 1.16 0.31–4.32 0.826 1.24 0.07–21.10 0.881
T-stage
T2-3 versus T1 2.80 0.70–11.25 0.146 3.13 0.38–25.76 0.288
N-stage
N1-N2 versus N0 5.02 1.25–20.14 0.023 2.44 0.24–24.88 0.451
Tumor grade
3 versus 1–2 0.71 0.18–2.85 0.631 0.64 0.14–2.97 0.571
mGluR1
Pos versus neg 5.23 1.40–19.60 0.014 8.60 1.06–70.19 0.044
Chemotherapy
Yes versus no 0.67 0.17–2.67 0.566 1.67 0.14–20.39 0.688
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:22292  | https://doi.org/10.1038/s41598-020-79248-4
www.nature.com/scientificreports/
Several lines of evidence suggest that mGluR1 contributes to malignant behavior in breast cancer. 
First, mGluR1 overexpression transforms cells to a malignant phenotype with increased proliferation and 
 invasion13,26,27. Second, reduction of mGluR1 activity in TNBC results in tumor suppression and reduced 
 angiogenesis18. Finally, mGluR1 can operate as a regulator of inflammation by creating an immunosuppressive 
tumor microenvironment resulting in inhibition of antitumor  activity28,29. With regard to the clinical connection 
between expression of mGluR1 and aggressiveness, in the entire cohort there was no association between the 
expression of mGluR1 and MFS or OS. However, in ER-negative breast cancer, and the aggressive TNBC subset, 
mGluR1 expression marks cancer with unfavorable outcome. Based on RNA (GRM1) expression, Mehta et al. 
reported that low GRM1 expression was associated with longer MFS in tamoxifen treated ER-positive breast 
 cancer8. Although these authors also observed a negative correlation between mGluR1 expression and prognosis, 
our data do not confirm an association between mGluR1 expression and prognosis in ER-positive breast cancer. 
Also in ER-positive patients receiving adjuvant tamoxifen we did not find such correlation (p = 0.29). This dif-
ference may be explained by methodological issues as Mehta et al.8 studied GRM1 at the RNA level whereas in 
our study mGluR1 was determined at the protein level.
To support our findings, we performed survival analysis for GRM1 RNA expression in TNBC patients from 
several cohorts but no significant relationship with outcome was  observed20–23. However, datasets are relatively 
small and differences in protein expression are not always correlated to RNA expression levels. More studies are 
needed to clarify the relation between mGluR1 expression, at both the mRNA and protein level, and prognosis 
in breast cancer. In addition, the major factors that regulate mGluR1 protein expression need further study.
Why mGluR1 expression is linked to poor outcome in hormone receptor negative tumors only, is not under-
stood. Differences in downstream activation of mGluR1 through glutamate between hormone sensitive versus 
hormone refractory tumors may explain the difference in prognostic value of mGluR1 in hormone receptor 
Figure 3.  Kaplan–Meier estimates of MFS as a function of mGluR1 expression in ER-negative breast cancer 
and TNBC. Kaplan–Meier estimates of MFS: (a) ER-negative breast cancer; and (b) TNBC. Patients were 
divided into two groups based on mGluR1 expression. Positive mGluR1 expression is depicted in dark blue lines 
and negative mGluR1 expression is depicted in light blue lines.
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positive versus the important hormone receptor negative breast cancer  subgroup30–32. However, differences in 
immune suppression may be an alternative explanation. TNBC is a heterogeneous group of  cancers33, and it is 
also conceivable that mGluR1 is a marker of a more aggressive subtype within TNBC.
New therapies are an urgent medical need, especially for the more aggressive TNBC that can only be treated 
with cytotoxic chemotherapy. However, also for other breast cancer subgroups new targets are needed as a signifi-
cant number of tumors will develop resistance to current  therapies34,35. Several studies have shown that mGluR1 
is a potential therapeutic target in breast  cancer13,26. Most of these studies have been performed in TNBC only. 
A clinically available drug named riluzole is a glutamate release inhibitor and is currently under investigation 
as a potential treatment for breast cancer. However, in breast cancer cells the effect of riluzole is not dependent 
on mGluR1 and recently a riluzole trial in advanced melanoma patients failed to demonstrate an improved 
 outcome29,36,37. Thus, directly targeting mGluR1 rather than its ligand glutamate may be a better approach, as has 
been demonstrated by using a specific mGluR1 inhibitor in mice orthotopically carrying a TNBC  xenograft13. 
Another approach may be the use of mGluR1 targeting antibodies that either effectively block the receptor, elicit 
an immune response and/or deliver a toxic payload to mGluR1 expressing breast cancer cells.
Our study has several limitations. First, this is an older cohort, starting in 2000. The advantage of an older 
cohort is the maturity of the follow-up data. However, over time treatment strategies have changed, affecting 
outcome in breast cancer patients diagnosed today. Another limitation is the relatively small sample size of 
some breast cancer subgroups, in particular TNBC, for which our conclusion should be validated in a larger 
independent cohort.
Conclusions
Our study shows that mGluR1 expression is highly prevalent in most breast cancer subgroups. In addition, we 
show that in patients with ER-negative breast cancer or TNBC mGluR1 is an unfavorable prognostic marker 
independent of known clinical and histopathological prognostic factors. Clearly, independent validation of this 
prognostic value is required. Nonetheless, our data imply that mGluR1 has the potential to be a relevant target 
for the treatment of breast cancer.
Data availability
All data and materials are available and can be obtained from the corresponding author upon reasonable request.
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